http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-100357-U
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b79671b994c5869e69a3d590dac3358 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-00 |
| filingDate | 2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d7d5e5bd4a5ee3cbac4f8370f6ca3b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c730cfd2dd96a7bdf1101bbe9b5eca7 |
| publicationDate | 2015-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-100357-U |
| titleOfInvention | METHOD OF FORECASTING FRAGMENT FRAGMENT |
| abstract | A method for predicting fracture fusion includes clinical examination, radiography. Additionally, the determination of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS Τ 786), osteocalcin, oxyproline, and interleukin 6 (IL-6) levels is carried out in the patient's serum. With homozygous carrier 677-SS, heterozygous 786-TC, osteocalcin levels of 17.2-38.0 ng / ml, oxyproline 12-15 μmol / l, IL-6 3.3-8.8 ng / l predict fracture fusion. |
| priorityDate | 2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.